PL3062791T3 - Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym - Google Patents
Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnymInfo
- Publication number
- PL3062791T3 PL3062791T3 PL14858402T PL14858402T PL3062791T3 PL 3062791 T3 PL3062791 T3 PL 3062791T3 PL 14858402 T PL14858402 T PL 14858402T PL 14858402 T PL14858402 T PL 14858402T PL 3062791 T3 PL3062791 T3 PL 3062791T3
- Authority
- PL
- Poland
- Prior art keywords
- attention
- neurodegenerative disorder
- cognitive disorders
- dementia associated
- novel treatments
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896173P | 2013-10-28 | 2013-10-28 | |
| EP14858402.2A EP3062791B1 (en) | 2013-10-28 | 2014-10-28 | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
| PCT/US2014/062644 WO2015066019A1 (en) | 2013-10-28 | 2014-10-28 | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3062791T3 true PL3062791T3 (pl) | 2020-06-15 |
Family
ID=53005024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14858402T PL3062791T3 (pl) | 2013-10-28 | 2014-10-28 | Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9861594B2 (pl) |
| EP (1) | EP3062791B1 (pl) |
| JP (1) | JP6607852B2 (pl) |
| KR (1) | KR102266696B1 (pl) |
| CN (1) | CN105848655B (pl) |
| AU (1) | AU2014342520B2 (pl) |
| CA (1) | CA2928429C (pl) |
| ES (1) | ES2769780T3 (pl) |
| IL (1) | IL245090A0 (pl) |
| PL (1) | PL3062791T3 (pl) |
| WO (1) | WO2015066019A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI874834B (zh) | 2014-12-18 | 2025-03-01 | 瑞士商赫孚孟拉羅股份公司 | 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途 |
| CR20200621A (es) | 2018-06-21 | 2021-02-03 | Hoffmann La Roche | Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso |
| US11911373B2 (en) * | 2018-08-16 | 2024-02-27 | Technion Research & Development Foundation Limited | Attention evaluation and methods for medicating |
| US20250186369A1 (en) * | 2022-03-07 | 2025-06-12 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or prventing cocaine use disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL57240C (pl) | 1940-02-21 | |||
| US5352688A (en) | 1991-02-14 | 1994-10-04 | The Mount Sinai School Of Medicine Of The City University Of New York | Methods for the treatment of bradyphrenia in parkinson's disease |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| EP0641202A1 (en) | 1992-05-18 | 1995-03-08 | Smithkline Beecham Plc | Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and parkinson's disease |
| AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| DE60008697T2 (de) | 2000-03-28 | 2005-02-10 | Council Of Scientific And Industrial Research | Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide |
| BRPI0411800A (pt) | 2003-06-23 | 2006-08-08 | Neurochem Int Ltd | candidatos a fármacos e métodos para sua preparação |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| CA2551944A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| BRPI0519243A2 (pt) | 2004-12-22 | 2009-01-06 | Neurochem Int Ltd | mÉtodos e composiÇÕes para tratar doenÇas relacionadas a amilàide |
| EP1851190A4 (en) | 2005-01-18 | 2009-04-08 | Univ Florida | COMPOSITIONS AND METHODS FOR PAIN-RESISTANCE |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0505509D0 (en) | 2005-03-17 | 2005-04-27 | Ic Innovations Ltd | Compounds |
| CA2613631A1 (en) | 2005-06-23 | 2007-01-04 | Spherics, Inc. | Improved dosage forms for movement disorder treatment |
| DE102005029468A1 (de) | 2005-06-24 | 2006-12-28 | Plt Patent & Licence Trading Ltd. | Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms |
| WO2007022415A2 (en) | 2005-08-18 | 2007-02-22 | Pharmacopeia, Inc. | Substituted 2-aminothiazoles for treating neurodegenerative diseases |
| JP2009537532A (ja) | 2006-05-15 | 2009-10-29 | セネックス バイオテクノロジー,インク. | 腫瘍細胞増殖の選択的阻害剤としてのcdki経路阻害剤 |
| WO2008042755A2 (en) * | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| JP4142073B2 (ja) * | 2006-10-13 | 2008-08-27 | 株式会社コナミデジタルエンタテインメント | 表示装置、表示方法、ならびに、プログラム |
| CL2007003130A1 (es) | 2006-10-30 | 2008-05-30 | Boehringer Ingelheim Int | Uso de una formulacion de liberacion inmediata con un ingrediente activo seleccionado de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol monohidrato o una sal farmaceuticamente aceptable de este, para el tratamiento de la enferme |
| WO2008107335A1 (en) | 2007-03-05 | 2008-09-12 | F. Hoffmann-La Roche Ag | Aminoamides as orexin antagonists |
| WO2008113364A2 (en) | 2007-03-20 | 2008-09-25 | Recepticon Aps | Amino derivatives to prevent nephrotoxicity and cancer |
| MY156662A (en) | 2007-11-01 | 2016-03-15 | Acucela Inc | Amine derivative compounds for treating ophthalmic diseases and disorders |
| GB0808282D0 (en) | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| AU2009246572A1 (en) | 2008-05-16 | 2009-11-19 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| ES2545795T3 (es) * | 2009-04-09 | 2015-09-15 | Cognition Therapeutics, Inc. | Inhibidores del deterioro cognitivo |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| JP6245983B2 (ja) | 2010-08-11 | 2017-12-13 | ドレクセル ユニバーシティ | パーキンソン病におけるジスキネジアを治療するための新規d3ドーパミン受容体アゴニスト |
| DE102011015842A1 (de) | 2011-03-30 | 2012-11-08 | Olaf Lichtenberger | Fluorphenyl- und Fluormethoxyphenylalkylamine und deren Anwendung |
| TW201305624A (zh) * | 2011-07-27 | 2013-02-01 | Hon Hai Prec Ind Co Ltd | 導光板修復方法 |
| EP2747768A4 (en) * | 2011-08-25 | 2015-10-21 | Cognition Therapeutics Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES |
-
2014
- 2014-10-28 PL PL14858402T patent/PL3062791T3/pl unknown
- 2014-10-28 EP EP14858402.2A patent/EP3062791B1/en active Active
- 2014-10-28 ES ES14858402T patent/ES2769780T3/es active Active
- 2014-10-28 CA CA2928429A patent/CA2928429C/en active Active
- 2014-10-28 KR KR1020167014290A patent/KR102266696B1/ko not_active Expired - Fee Related
- 2014-10-28 WO PCT/US2014/062644 patent/WO2015066019A1/en not_active Ceased
- 2014-10-28 US US15/028,654 patent/US9861594B2/en active Active
- 2014-10-28 JP JP2016526782A patent/JP6607852B2/ja not_active Expired - Fee Related
- 2014-10-28 CN CN201480071543.0A patent/CN105848655B/zh not_active Expired - Fee Related
- 2014-10-28 AU AU2014342520A patent/AU2014342520B2/en not_active Ceased
-
2016
- 2016-04-13 IL IL245090A patent/IL245090A0/en unknown
-
2017
- 2017-11-22 US US15/821,340 patent/US10695302B2/en active Active
-
2020
- 2020-06-04 US US16/892,467 patent/US11744810B2/en active Active
-
2023
- 2023-09-05 US US18/242,036 patent/US20240074993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HK1225973A1 (zh) | 2017-09-22 |
| US9861594B2 (en) | 2018-01-09 |
| KR102266696B1 (ko) | 2021-06-21 |
| ES2769780T3 (es) | 2020-06-29 |
| IL245090A0 (en) | 2016-06-30 |
| AU2014342520B2 (en) | 2019-08-08 |
| US20180092865A1 (en) | 2018-04-05 |
| CN105848655B (zh) | 2019-11-08 |
| CN105848655A (zh) | 2016-08-10 |
| EP3062791A4 (en) | 2017-08-16 |
| US20240074993A1 (en) | 2024-03-07 |
| CA2928429A1 (en) | 2015-05-07 |
| US11744810B2 (en) | 2023-09-05 |
| CA2928429C (en) | 2022-08-30 |
| KR20160067193A (ko) | 2016-06-13 |
| JP2016540737A (ja) | 2016-12-28 |
| WO2015066019A1 (en) | 2015-05-07 |
| US10695302B2 (en) | 2020-06-30 |
| AU2014342520A1 (en) | 2016-05-05 |
| JP6607852B2 (ja) | 2019-11-20 |
| EP3062791B1 (en) | 2020-01-08 |
| US20160256417A1 (en) | 2016-09-08 |
| EP3062791A1 (en) | 2016-09-07 |
| US20200397721A1 (en) | 2020-12-24 |
| NZ718978A (en) | 2021-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201509101B (en) | Financial account with group authorization | |
| IL240337A0 (en) | Deviation alert | |
| EP3046470A4 (en) | Diagnosing and treating movement disorders | |
| GB201312279D0 (en) | Neurodegenerative disorders | |
| IL237742A0 (en) | Laquinimod and pridofidine for the treatment of neurodegenerative diseases | |
| GB201415523D0 (en) | Vehicle with a deflection device, and deflection device | |
| GB201305407D0 (en) | Media Distribution | |
| PL2956071T3 (pl) | Zestaw do blokady nerwów obwodowych | |
| GB201300538D0 (en) | Polycarbonates | |
| EP3026153A4 (en) | Thread production device, and aggregating part | |
| PT2986525T (pt) | Tampa com evidência de violaçâo | |
| SG11201506356WA (en) | Dehydration-hydrolysis processes and catalysts therefor | |
| IL245090A0 (en) | New treatments for attention disorders, cognitive disorders and dementia related to a neurodegenerative disorder | |
| PL2823971T3 (pl) | Osłona obręczy koła oraz koło z taką osłoną | |
| PL3901164T3 (pl) | Zaburzenia związane z glutenem | |
| IL276431A (en) | Treatment of the brain disorders and related symptoms | |
| SG11201509429UA (en) | Process for producing phenol and/or cyclohexanone | |
| PL3383851T3 (pl) | Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej | |
| GB2512235B (en) | Security apparatus with blocking element | |
| GB201420624D0 (en) | Security Lable | |
| SG11201509522UA (en) | Process for producing phenol and/or cyclohexanone | |
| SG11201603200VA (en) | Process for making phenol and/or cyclohexanone | |
| EP2909429A4 (en) | INTERVAL CONTROL VALVE WITH DIFFERENT RADIAL INTERIORS | |
| GB201413912D0 (en) | Circular foal feeder | |
| TWM476059U (en) | Hub |